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Abstract In the rat liver, transcription of the serine:pyruvate/
alanine:glyoxylate aminotransferase (SPT/AGT) gene occurs
from two sites, +1 and +66, in exon 1, resulting in the formation
of two mRNAs, one for a precursor of mitochondrial SPT/AGT
and the other for peroxisomal SPT/AGT, respectively. In this
study, we attempted to characterize the downstream promoter
responsible for generation of peroxisomal SPT/AGT. The
minimal downstream promoter was confined to the +21^+90
region. We demonstrated that C/EBPK and C/EBPL bound
around the downstream start site (+66) contribute to the
promoter activity. The downstream promoter activity is also
regulated positively by a short inverted repeat, located 20^30 bp
upstream of the downstream start site, through a protein
factor(s) bound to this region. On the other hand, the sequence
just downstream of the start site may negatively regulate the
promoter activity. ß 2001 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
Serine:pyruvate/alanine:glyoxylate aminotransferase (SPT/
AGT), which is expressed speci¢cally in the liver, is a unique
enzyme with dual species-speci¢c and food habit-dependent
organelle distributions and with dual functions. As for its
organelle distribution, this enzyme is entirely peroxisomal in
humans and herbivores and is largely mitochondrial in carni-
vores [1^4]. In the rat liver, this enzyme is located in both
mitochondria and peroxisomes, and only the mitochondrial
enzyme is greatly induced by administration of glucagon
[5,6]. The marmoset, a New World monkey, also has SPT/
AGT in both mitochondria and peroxisomes in the liver [4].
As for its function, SPT/AGT is involved in both the metab-
olism of L-serine and glyoxylate, and this enzyme plays an
important role in serine metabolism irrespective of its mito-
chondrial or peroxisomal localization [7]. With respect to the
glyoxylate metabolism, on the other hand, the major path-
ways of hepatic glyoxylate production in herbivores and car-
nivores appear to be oxidation of glycolate in peroxisomes
and metabolism of hydroxyproline in mitochondria, respec-
tively. Thus, the proper organelle destination of SPT/AGT
may be important for the respective animal species to e⁄-
ciently metabolize glyoxylate, because glyoxylate can other-
wise be oxidized to oxalate, a useless and even toxic end-
product of metabolism [8].
We have previously shown that transcription of the rat
SPT/AGT gene occurs from two start sites in exon 1 [9]. Tran-
scription from the upstream start site (+1) generates an
mRNA for a 45-kDa precursor for mitochondrial SPT/AGT
containing a mitochondrial targeting signal (MTS) of 22
N-terminal amino acids. The precursor is translocated into
mitochondria and converted to the mature size (43 kDa) by
processing. On the other hand, transcription from the down-
stream start site (+66) generates an mRNA that encodes a
product of mature size. The product is then directed to per-
oxisomes by an intramolecular peroxisomal targeting signal
(PTS) [9^11]. When glucagon is injected into rats, only the
upstream site-derived mRNA is greatly induced by transcrip-
tion activation through cAMP and protein kinase A [12,13].
The downstream site-derived mRNA appears to be constitu-
tive, although its amount is very low. Thus, the most out-
standing feature of this gene is that alternative usage of the
two promoters eventually determines organelle localization of
the expression product. Danpure et al. showed that transcrip-
tion of the SPT/AGT gene in the cat occurs almost entirely
from a single site corresponding to the upstream start site in
the rat SPT/AGT gene, consistent with the largely mitochon-
drial localization of SPT/AGT [14]. Similar start sites were
also found in the case of rabbits and humans, but the up-
stream AUG codon for translation of the N-terminal MTS
sequence in these species had been mutated to ACA or AUA
[15,16]. Therefore, the ¢rst methionine codon encountered in
translation should be the downstream AUG corresponding to
N-terminal methionine of mature SPT/AGT, consistent with
the entirely peroxisomal localization of the enzyme. In the
marmoset, however, two SPT/AGT mRNAs were found, sug-
gesting that transcription was initiated from two di¡erent
sites, as in the case of the rat [16]. It appears that the down-
stream transcription start site has been used to distribute SPT/
AGT to peroxisomes in addition to mitochondria. We have
been interested in how the downstream transcription start site
was constructed in the rat and marmoset during evolution.
Transcription initiation is a complex process requiring as-
sembly of many transcriptional factors on the promoter. The
most common core promoter elements, which can act inde-
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pendently or in concert to determine the transcription start
site, are the TATA box located about 30 bp upstream of the
start site and an initiator element (consensus sequence: Py-
PyANTPyPy) at the start site. The initiator element is capable
of functioning in concert with either or both a TATA box and
multiple upstream binding sites for some activators such as
GC box for the Sp1 activator [17]. In a promoter containing a
TATA box and strong activators, such as Sp1 and a CCAAT-
binding protein, initiator activity does not contribute greatly
to the core promoter, whereas in the absence of a TATA box,
the initiator plays a major role in the promoter activity, which
can be abolished completely when some mutations are intro-
duced into the initiator sequence [18,19]. Within the consensus
initiator sequence, PyA(+1)NT/A is the most critical for the
strength of an initiator, and pyrimidines must surround the
sequence [18]. Our previous studies indicated that the down-
stream promoter of the rat SPT/AGT gene is located between
+21 and +106 [20]. However, this region contains neither a
TATA box nor a consensus initiator sequence. In this study,
we found that C/EBPK and C/EBPL are positively implicated
in the downstream promoter activity of the rat SPT/AGT
gene. The results also suggested that the sequence just
downstream of the +66 start site might negatively regulate
the promoter activity through its binding to unidenti¢ed fac-
tor(s).
2. Materials and methods
2.1. Plasmid constructs
The origins and methods for construction of basal promoterless
CAT plasmids, pSV001CAT and pSV001-mt, and test CAT plasmids
containing rat SPT/AGT 5P-sequences of various lengths,
pHR1362CAT (31256^+106), pDR85CAT (+21^+106) and
pNR69CAT (+37^+106), were described previously [20]. pDB70CAT
(+21^+90) and pEnR212CAT (3102^+106) were constructed by in-
serting the DdeI (+21) ^ BstNI (+90) fragment and HindIII (3102) ^
RsaI (+106) PCR fragment of the SPT/AGT gene into the NruI^
EcoRV site and the HindIII^EcoRV site of pSV001CAT, respectively.
pEnB196CAT (3102^+90) was constructed by double ligation of the
HindIII (3102) ^ NheI (+37) and NheI (+37)^BstNI (+90) PCR frag-
ments into the HindIII^EcoRV site of the pSV001CAT. Site-directed
mutagenesis was performed using mismatched primers and 320pUC18
containing the PvuII (3191)^PvuII (+128) fragment of the SPT/AGT
gene as a template. Oligonucleotides are as follows: m1 (AGGC-
CTCGC CTCTGcagTCAGCCCAGAGCTA), m2 (TCTGAGTT-
CAGCtgAGAGCTAGCTGGGAAA), m3 (TTCAGCCCAGAGa-
gAGCTGGGAAAT), m4 (TTCAGCCCAGAGCTctCTGGGAAA-
TGTT), m5 (TTCAGCCCAGAGCTAGagGGGAAATGTT), m6
(AGCTAGCTGGGAccTGTTCCGGAT), m7 (TTCCGGATGTTG-
GCCAtGGCCAGTGTGACG), m8 (TGTTCGGATGTTGaCCAtG-
GCCAGTGTGA), m9 (GATGTTGGCCAAcagCAGTGTGACGC
TG) and m10 (TGGGAAATGTTCCtGcTGTTGGCCAA) were
used as mismatched primers. The PCR products, HindIII (3102)^
RsaI (+106) and DdeI (+21)^RsaI (+106) fragments containing vari-
ous mutations, were then ligated to the HindIII^EcoRV site and
NruI^EcoRV site of pSV001CAT, respectively. All of the SPT gene
fragments described above were fused to the 5P-end of CAT cDNA to
make ATG triplets within the SPT/AGT gene and the CAT cDNA
out-of-frame with each other, so that mRNAs derived from the up-
stream start site would not be responsible for CAT activities in this
study. Plasmids containing C/EBPK cDNA (MSV/EBPK) or C/EBPL
cDNA (MSV/EBPL) were kind gifts from Dr. Steven L. McKnight
(University of Texas Southwestern Medical Center, TX, USA). A C/
EBPK expression vector, pcDNA3.1-C/EBPK, and a C/EBPL expres-
sion vector, pcDNA3.1-C/EBPL, were then constructed by inserting
the BamHI^HindIII fragment of MSV/EBPK and the EcoRI^XhoI
fragment of MSV/EBPL into the BamHI^EcoRV site and the
EcoRI^XhoI site of pcDNA3.1 (Invitrogen), respectively. An expres-
sion vector of a dominant-negative inhibitor of C/EBP, CMV500-
4hep-C/EBP [21,22], was a generous gift from Dr. Charles R. Vinson
(National Institute of Health, MA, USA).
2.2. Cell culture and transient transfection
Human hepatoma-derived HepG2 cells were grown in Dulbecco’s
modi¢ed Eagle’s medium supplemented with 10% fetal calf serum to
40^60% con£uence in 6-well plates, and they were then transfected by
the calcium phosphate precipitation method using a total of 1.6^1.9
Wg of a DNA mixture containing 1.0^1.3 Wg of test plasmid and 0.6 Wg
of SV40-L-gal as a transfection control. To determine the e¡ects of
C/EBPs on the reporter gene expression, 0.5^1.0 Wg of pcDNA3.1-
C/EBPK or pcDNA3.1-C/EBPL was co-transfected with 0^0.5 Wg of
CMV500-4hep-C/EBP, 1.0 Wg of a reporter plasmid (pDR85CAT),
and 0.05 Wg of RSV-L-gal as an internal control. Cells were washed
with phosphate-bu¡ered saline 6 h after the transfection, and then the
culture was continued for an additional 42 h. Cell extracts were pre-
pared 48 h after the transfection by freeze^thawing, and the CAT
activity was measured as described by Gorman et al. [23]. All trans-
fections were performed in duplicate and repeated at least three times.
2.3. Preparation of probes and competitors
An annealed synthetic complementary oligonucleotide correspond-
ing to +21^+50 and that corresponding to +50^+76 of the rat SPT/
AGT gene were end-labeled with [Q-32P]ATP using T4 polynucleotide
kinase and used as probes for electrophoretic mobility shift assays
(EMSAs). Double-stranded oligonucleotides corresponding to various
cis-elements or mutated SPT/AGT gene were used as competitors. The
sequences of the competitors were as follows: C/EBP, 5P-TGCA-
GATTGCGCAATCTG CA-3P ; C/EBP mutant, 5P-TGCAGAGAC-
TAGTCTCTGC A-3P. Mutated competitors (M2, M5, M7, M8, M9
and M10) are shown in Figs. 2A and 4A.
2.4. EMSA
Nuclear extracts were prepared from HepG2 cells as described pre-
viously [24]. In competitive binding experiments, nuclear extracts (5 Wg
protein) were preincubated with 3 Wg of poly[d(I-C)] and a 50-or
100-fold molar excess of unlabeled competitors for 15 min on ice in
a binding bu¡er (50 mM Tris^HCl, pH 7.9, 12.5 mM MgCl2, 1 mM
EDTA, 50 mM KCl, 5% (v/v) glycerol), followed by the addition of
10 fmol of an end-labeled probe. For a supershift assay, nuclear ex-
tracts were preincubated for 15 min on ice with 2 Wl of an antibody
against C/EBPK, C/EBPL or C/EBPN (Santa Cruz Biotechnology, CA,
USA) or with preimmune serum as a control, prior to the addition of
10 fmol of an end-labeled probe. Then samples were incubated with
the probe for 30 min on ice, applied to 5% polyacrylamide gel in
0.25UTris borate/EDTA bu¡er, and subjected to electrophoresis at
12.5 mA at 4‡C.
3. Results
3.1. The minimal downstream promoter is located within the
region from +21 to +90
To identify the region essential for the promoter activity for
transcription from the downstream start site, various deletion
mutants of the putative downstream promoter region of the
rat SPT/AGT gene were linked to the CAT gene and each of
them was transiently expressed in HepG2 cells (Fig. 1A). For
the following reasons, we consider that CAT activity mea-
sured in this study re£ects only the downstream promoter
activity. First, since the ATG triplet within the SPT/AGT
gene at +114 to +116, which is supposed to be the N-terminal
Met of SPTp, was eliminated in these constructs [20], the ¢rst
Met codon encountered in translation of the downstream site-
derived mRNA should be the initiation AUG (the third aster-
isk in Fig. 1A) for CAT, resulting in the expression of native
CAT. In translation of the upstream site-derived mRNA, on
the other hand, the translation begins from the AUG at +48
to +50 (the ¢rst asterisk), which corresponds to N-terminal
Met of the SPTm-mRNA, but the CAT gene-derived AUG
codon is expected to be out-of-frame, resulting in production
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of inactive SPT-CAT fusion protein. Second, promoter activ-
ity of the region 3102 to +36 containing neither the down-
stream start site nor the initiation ATG was less than 7^10%
of that of the region 3102 to +106 in which the ATG triplet
was out-of-frame of the CAT-coding sequence. In addition,
the region 3102 to +106 containing ‘in-frame’-ATG showed
almost the same activity as that of the same region containing
‘out-of-frame’-ATG, suggesting that the region 3102 to +106
contributes greatly to promotion of the transcription from the
downstream start site (data not shown, manuscript in prepa-
ration). In fact, as we showed by RNase protection analysis in
our previous study [13], the basal level of endogenous mito-
chondrial SPT mRNA in the rat liver or in primary rat hepa-
tocytes is considerably lower than that of peroxisomal SPT
mRNA.
Deletion of the 5P region from 31256 to 3103 increased the
transcriptional activity by about 3-fold, suggesting the pres-
ence of a negative element. Further deletion from 3102 to
+20 resulted in only a slight decrease. Upon subsequent dele-
tion from +21 to +36, the promoter activity was further de-
creased by 80%. No change in the promoter activity was ob-
served when the 3P region was deleted from +91 to +106.
These results suggest that the minimal downstream promoter
is located in the +21^+90 region. The nucleotide sequence of
Fig. 2. Involvement of the short inverted repeat in the downstream
promoter activity. A: Schematic representation of wild-type
pEnR212CAT (wt) and its mutated CAT reporter plasmids (mt1 to
mt6) that harbor mutations in or around the inverted repeat. The
nucleotide sequence corresponding to positions +21 to +50 in the
SPT/AGT downstream promoter region is shown, and mutated nu-
cleotides are indicated by bold underlines. A pair of opposite arrows
denotes the short inverted repeat. In EMSA, +21^+50 fragments
containing mutations in one side of the short inverted repeat were
used as competitors (M2 and M5). B: EMSA was performed with
10 fmol of a 32P-labeled +21^+50 fragment of the SPT/AGT gene
as a probe and 5 Wg of nuclear extracts from HepG2 cells, as
described in Section 2. Arrows show DNA^protein complexes.
(C) Relative CAT activities. HepG2 cells were transfected transiently
with each promoter reporter plasmid described in (A). CAT activ-
ities are expressed relative to the activity obtained with wild-type
pEnR212CAT. All values are means þ S.D. of three separate experi-
ments. Wt, wild-type.
Fig. 1. Functional analysis of rat SPT/AGT promoter deletion mu-
tants in HepG2 cells (A). In the schematic representation of rat
SPT/AGT deletion mutants fused to the CAT reporter gene, the up-
stream and downstream transcription start sites are shown by hook-
shaped arrows. Horizontal bars represent the SPT/AGT 5P-sequen-
ces with the nucleotide positions of the 5P- and 3P-ends relative to
the upstream transcription start site. ATG triplets are indicated by
asterisks. Note that the translation product of mRNA synthesized
from the +1 site is out-of-frame of the CAT-coding gene. HepG2
cells were transfected transiently with each reporter plasmid and
SV40-L-gal as a control for transfection e⁄ciency. CAT activities
are expressed relative to the activity obtained with pDR85CAT.
Values are means þ S.D. of three separate experiments. B: Nucleo-
tide sequence of the downstream promoter region of the rat SPT/
AGT gene. The predetermined downstream transcription start site
(+66) is shown by a hook-shaped arrow. A pair of opposite arrows
denotes the short inverted repeat. Open squares indicate the putative
C/EBP binding sequences. Consensus sequences for the C/EBP site:
T(G/T)NNGNAA(G/T).
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the minimal promoter region is shown in Fig. 1B. The tran-
scription start site for generation of mRNA for peroxisomal
SPT/AGT had been determined to be at +66 [9]. Although no
TATA-like sequence is present, there is a short inverted repeat
(CCCAGAGCTAGCTGGG) at 20^35 bp upstream of the
downstream start site. Three C/EBP binding sites are also
located close to or overlapping the start site.
3.2. The short inverted repeat is involved in transcriptional
regulation
The results showing that the +21^+36 region was requisite
for the promoter activity prompted us to examine nuclear
factor binding to this region by an EMSA using nuclear ex-
tracts from HepG2 cells. As shown in Fig. 2B, two bands were
detected when the +21^+50 fragment was used as a probe,
suggesting that some protein^DNA complexes had been
formed. A complex was not detected in the presence of a
100-fold molar excess of an unlabeled self-competitor (Fig.
2B, lane 3). However, no competition was observed with the
same molar excess of a competitor that covered only the 5P- or
3P portion of the probe (fragments +21^+37, +21^+42 and
+37^+90) or with the consensus C/EBP site (Fig. 2B, lanes
4^6 and 9). When the competitor contained mutations in one
side of the short inverted repeat (M2 and M5, Fig. 2A), the
competition was only partial (Fig. 2B, lanes 7 and 8). These
results suggest that the short inverted repeat is the most likely
binding site of factors that might be involved in the down-
stream promoter activity.
To examine whether the short inverted repeat is actually
involved in transcriptional regulation, 3102^+106 fragments
containing the same mutations as those used in the gel shift
assay were linked to the CAT gene (Fig. 2A), and each of
them was transiently expressed in HepG2 cells (Fig. 2C). Mu-
tations in either side of the inverted repeat (mt2, mt5) caused
an approximately 80% decrease in the promoter activity,
whereas mutations outside or in the intervening portion of
the inverted repeat (mt1, mt3, mt4 and mt6) resulted in only
a slight decrease. These ¢ndings further suggest that the short
inverted repeat is involved in the promoter activity. The pro-
tein factors that bind to this region remain to be identi¢ed.
3.3. C/EBP binds to the downstream promoter of the
SPT/AGT gene
To examine whether C/EBP binds to the putative C/EBP
binding sites located close to or overlapping the downstream
transcription start site, EMSA was performed using the +50^
+76 fragment as a probe and nuclear extracts from untrans-
fected HepG2 cells or C/EBP-transfected cells. In our prelimi-
nary experiments, the mobility shift pattern observed with the
+50^+76 fragment as a probe was essentially the same as that
obtained with the +50^+90 fragment. As judged from the
competition by a 50-fold molar excess of an unlabeled self-
competitor, the nuclear extract from untransfected cells gave
two speci¢c protein^DNA complexes (I and II, Fig. 3A,B,
lane 2). The formation of the upper complex (I) was inhibited
by a 50-fold molar excess of a fragment corresponding to the
C/EBP site, but no competition was observed by the same
molar excess of the mutated C/EBP site (Fig. 3A, lanes 4
and 5). In addition, complex (I) disappeared almost com-
pletely when nuclear extracts from untransfected cells were
preincubated with an antibody against C/EBPK. An antibody
against C/EBPL also caused partial disappearance of complex
(I) but that against C/EBPN had no e¡ect (Fig. 3A, lanes 6^8).
The disappearance seemed to be caused by supershift of com-
plex (I), since a weak and smeared band was observed near
the origin of the gel when exposed for a longer time (data not
shown). It has been reported that C/EBPs are expressed at low
levels in the hepatoma cell line HepG2 [25], although C/EBPK
Fig. 3. Binding of C/EBP to the downstream promoter region of the SPT/AGT gene. EMSA was performed with a +50^+76 fragment as a
probe and nuclear extracts from untransfected HepG2 cells (A) or HepG2 cells transiently transfected with a C/EBPK or C/EBPL expression
plasmid (B, C). The sequences of the competitor oligonucleotides used, C/EBP, and C/EBP mutant (C/EBP mut) are given in Section 2. The
procedures for the supershift assay are also described in Section 2. Arrows indicate speci¢c complexes (I, IP, II), and arrowheads indicate the
supershifted bands. Asterisks represent non-speci¢c bands. The lower non-speci¢c band did not appear in (B) despite the fact that the same ex-
tracts as those used in (A) and (C) were used.
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and C/EBPL are highly expressed in the adult liver [26]. The
amount of C/EBP in untransfected HepG2 cells was probably
too low to be detected signi¢cantly as a supershifted band in
these experimental conditions. To determine the interaction
with C/EBP more clearly, we performed EMSA with nuclear
extracts from HepG2 cells transiently transfected with a
C/EBPK or C/EBPL expression plasmid. In the case of the
extracts from cells transfected with the C/EBPK expression
plasmid, complex (IP) was observed in addition to complexes
(I) and (II). Formation of protein complexes (I) and (IP) were
e¡ectively inhibited by the unlabeled +50^+76 fragment (Fig.
3B, lanes 5^6, and Fig. 3C, lanes 1^2) and the consensus
C/EBP site (Fig. 3C, lane 3). We assume that the large com-
plex of (I) and (IP) consists mainly of KK-heterodimers with
some KL-heterodimers of C/EBP. Assuming, based on the
results of a supershift assay shown in Fig. 3A, that C/EBPK
is a major contributor to complex (I) formation and that
C/EBPL is induced by C/EBPK as in the case of the Xenopus
C/EBP [27], formation of KK- and KL-complexes and their
binding to the SPT gene would occur to a greater degree.
This may be the reason why the anti-C/EBPK antibody per-
fectly supershifted both complexes and the anti-C/EBPL anti-
body was partially e¡ective as well (Fig. 3C, lanes 4 and 5). It
is not clear at present, however, which complex of (I) and (IP)
corresponds to KK- or KL-dimers. When nuclear extracts from
C/EBPL-overexpressing cells were used, a speci¢c protein^
DNA complex that showed a similar pattern of migration
to that of complex (IP) was formed. The formation of this
complex was completely inhibited by a fragment of the con-
sensus C/EBP site, and the complex was supershifted by anti-
C/EBPL antibody (Fig. 3C, lanes 6^10). Taken together, these
results indicate that C/EBPK and C/EBPL are able to bind to
the downstream promoter around the transcription start site.
On the other hand, complex (II) showed competition with a
50-fold molar excess of an unlabeled self-competitor but not
with a fragment of the C/EBP site. Competitors correspond-
ing to the DNA recognition sites of known initiator binding
proteins, including YY1, USF1 and TFII-I, were also without
e¡ect (data not shown). It remains unclear why the signal of
complex (II) was weak in the assay with C/EBPL-overexpress-
ing nuclear extracts.
3.4. The putative C/EBP binding sites are involved in the
downstream promoter activity
To determine the function of the putative C/EBP binding
sites, various mutations were introduced into the vicinity of
the downstream start site in the context of pEnR212CAT
(Fig. 4A), and CAT assays were carried out. As shown in
Fig. 4B, introduction of mutations into either of the two pu-
tative C/EBP sites, one located just upstream of the +66 start
site and the other partially overlapping the start site, resulted
in a 40^60% decrease in the promoter activity (mt7, mt8 and
mt10). On the other hand, introduction of a mutation into a
downstream region of the start site (mt9) gave rise to a mod-
est increase (2-fold) in the promoter activity. In EMSA, both
complex (I) and complex (II) showed partial competition with
a 50-fold molar excess of two unlabeled mutated competitors
(M7 and M8, Fig. 4C, lanes 4 and 5). A mutated competitor,
M10, competed partially for complex (I) and competed per-
fectly for complex (II) (Fig. 4C, lane 7). Interestingly, a mu-
tated competitor, M9, competed for complex (I) but not for
complex (II) (Fig. 4C, lane 6). Taken together, these results
suggest that the two C/EBP sites are involved in the binding
of C/EBP and activate transcription from the downstream
start site. The results also suggest that an unknown factor
that is responsible for the formation of the complex (II)
may bind to the region overlapping or just downstream of
the initiation site. Inhibition by the mutations of this factor’s
binding to this region might be involved in the increase in M9
promoter activity.
3.5. C/EBPK and C/EBPL activate the minimal promoter of the
SPT/AGT gene in HepG2 cells
To examine further whether C/EBPs function in the expres-
Fig. 4. Involvement of the putative C/EBP binding sites in the
downstream promoter activity. A: Schematic representation of wild-
type pEnR212CAT (Wt) and its mutated CAT reporter plasmids
that harbor mutations in the C/EBP binding sites (m7, m8 and
m10) or downstream of the start site (m9). The nucleotide sequence
corresponding to positions +50^+76 bp in the SPT/AGT promoter
region is shown, and mutated nucleotides are indicated by bold
underlines. The hook-shaped arrow shows the predetermined down-
stream transcription initiation site (+66). In EMSA, +50^+76 frag-
ments containing various mutations, described above, were used as
competitors (M7^M10). B: Relative CAT activity. HepG2 cells were
transfected transiently with each promoter reporter plasmid de-
scribed in (A). CAT activities are expressed relative to the activity
obtained with wild-type pEnR212CAT. All values are means þ S.D.
of three separate experiments. C: EMSA was performed with 10
fmol of a 32P-labeled +50^+76 fragment of the SPT/AGT gene as a
probe and 5 Wg of nuclear extracts from HepG2 cells, as described
in Section 2. Arrows indicate two speci¢c complexes (I, II). Aster-
isks represent non-speci¢c bands. Wt, wild-type.
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sion of the SPT/AGT gene, an expression vector of C/EBPK
or C/EBPL was co-transfected with pDR85CAT (Wt) into
HepG2 cells (Fig. 5). Overexpression of both C/EBPK and
C/EBPL resulted in an approximately 3-fold increase in the
basal expression of pDR85CAT. The enhancement of the ex-
pression by C/EBPs was reduced by co-expression of a dom-
inant-negative inhibitor of C/EBP (DN-C/EBP) that forms an
inactive heterodimeric complex with C/EBP [21,22]. Transfec-
tion of 1 Wg of the DN-C/EBP plasmid alone caused an ap-
proximately 40% decrease in the promoter activity (data not
shown). DN-CEBP did not completely block the promoter
activity, possibly because of the unidenti¢ed factor(s) that
binds to the promoter region (see Fig. 2), where it may play
an additional important role in the regulation of the down-
stream promoter. Co-transfection of a C/EBPK or C/EBPL
expression vector with pDR85mt, which contains the same
mutated C/EBP binding site as the mt8 vector depicted in
Fig. 4A, had no e¡ect. These results demonstrate that
C/EBPK and C/EBPL transactivate the downstream promoter
of the SPT/AGT gene through the C/EBP binding sites.
4. Discussion
SPT/AGT is a liver-speci¢c enzyme with unique features of
dual species-speci¢c and food habit-dependent organelle dis-
tributions. It is located largely in mitochondria in carnivores
and entirely in peroxisomes in herbivores. In the rat, SPT/
AGT is distributed in both mitochondria and peroxisomes,
and the transcription of the rat SPT/AGT gene occurs from
two start sites in exon 1 [9]. As described in Section 1, the
downstream transcription initiation appears to be used as a
means to distribute SPT/AGT to peroxisomes in addition to
mitochondria. In the present study, we identi¢ed several cis-
acting regulatory elements, including a short inverted repeat
and C/EBP binding sites in the downstream promoter region.
The short inverted repeat was located 20^35 bp upstream of
the downstream start site and was found to be involved in
transcriptional regulation. We found that the downstream
promoter activity was controlled by C/EBP binding sites lo-
cated around the downstream start site. Our results also in-
dicated the possibility that an unknown factor might bind to
the initiation site overlapping a C/EBP binding site to regulate
the promoter.
Many cellular genes contain a wide variety of core pro-
moter elements. Some genes contain only a TATA box, while
others contain an initiator element of PyPyA(+1)NT/APyPy
[18] in addition to or instead of a TATA box, or neither a
TATA box nor an initiator. Furthermore, some genes exhibit
a single transcriptional start site, whereas others exhibit multi-
ple start sites. The downstream promoter region of the rat
SPT/AGT gene contains no such cis-elements that would spec-
ify the site of transcription initiation, except for the initiator-
like sequence of CCA(+1)AGGC. This sequence seems to be
quite di¡erent from the known strong initiators such as the
adenovirus major late promoter, terminal deoxynucleotidyl-
transferase gene promoter, and dihydrofolate reductase gene
promoter [28], because it has been demonstrated that
CA(+1)NT/A is the most important core sequence and that
substitution of T/A(+3) with C/G, or following pyrimidines
with purines, resulted in a signi¢cant reduction of promoter
activity [18,19]. Besides, we did not ¢nd any speci¢c contribu-
tions of the known initiator-binding factors such as YY-1,
E2F/HIP1, TFII-I and USF-I to the formation of a protein
complex with the SPT promoter. Moreover, neither the
TATA box, GC box, nor CCAAT box, which serve as major
regulatory elements within core promoters of many genes, was
found. Therefore, we have been interested in a unique mech-
anism underlying the regulation of the TATA-less promoter
of the SPT/AGT gene.
Sequence analysis of the downstream promoter revealed the
presence of a short inverted repeat 20^35 bp upstream of the
predetermined downstream start site. This short inverted re-
peat was subsequently shown to play an important role in the
promoter activity by EMSA and transient CAT reporter anal-
ysis with a series of 5P-SPT/AGT gene constructs containing
various mutations. Inverted repeat DNA sequences have the
potential to form a cruciform structure through intra-strand
base pairing, and the cruciform-binding proteins may be in-
volved in the regulation of DNA transcription and replication
[29]. In this study, however, it was not determined whether the
short inverted repeat in the rat SPT/AGT gene could form a
cruciform structure or whether the structure is involved in
transcription regulation.
C/EBPs form a family of transcriptional factors that are
crucial for cellular di¡erentiation and functions in a variety
of tissues. At least six members [30], C/EBPK, C/EBPL,
C/EBPQ, C/EBPN, C/EBPO and C/EBPj (also known as
CHOP), have been identi¢ed. Each of these proteins consists
of an activation domain, a DNA-binding basic region, and a
leucine-rich dimerization domain. Dimerization through the
leucine zipper leads to the formation of homo- and hetero-
dimers, which bind with their DNA-binding basic regions to a
common palindromic DNA sequence of TT/GNNGNAAT/G
in the promoter^enhancer region of a variety of genes [31].
In this study, HepG2 cells were used for functional analysis
of the SPT/AGT downstream promoter. In neoplastic hepa-
Fig. 5. Activation by C/EBPK and C/EBPL of the downstream pro-
moter activity. A C/EBPK expression vector (C/EBPK), pcDNA3.1-
C/EBPK, or a C/EBPL expression vector (C/EBPL), pcDNA3.1-
C/EBPL, was co-transfected with wild-type pDR85CAT (Wt) or a
mutated CAT reporter plasmid (pDR85mt) containing the same mu-
tated C/EBP binding site as the mt8 vector. A dominant-negative in-
hibitor of C/EBP (DN-C/EBP) was co-expressed with C/EBPK or
C/EBPL. CAT activities are expressed relative to the activity ob-
tained with wild-type pDR85CAT. All values are means þ S.D. of
three separate experiments.
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tocytes, including HepG2 cells, basal expression of C/EBPK is
known to be very low [25], unlike in mature hepatocytes,
where C/EBPK is strongly and constitutively expressed [26].
The C/EBPL expression level in these cells is higher than that
of the K isoform but still lower than that in the adult liver.
Therefore, the contribution, if any, of C/EBP to the basal
promoter activity may be low in HepG2 cells because of its
low content. However, when HepG2 cells were forced to over-
express C/EBPK or C/EBPL, much stronger signals of C/EBP-
speci¢c bands were observed in EMSA (Fig. 3B,C), and the
promoter activity was increased by about 3-fold in the CAT
assay (Fig. 5), while the increase was suppressed by co-expres-
sion of dominant-negative inhibitor of C/EBP. Unfortunately,
we could not achieve a complete suppression by the domi-
nant-negative inhibitor to below the basal level of the down-
stream promoter activity, because the lower level of expres-
sion of the wild-type C/EBP reduced the promoter activation
and the higher level of expression of the dominant-negative
inhibitor caused cell death. Nevertheless, our results strongly
suggest that C/EBP binds to and activates the downstream
SPT/AGT promoter. Since it is known that C/EBPK and
C/EBPL play important roles in transcription regulation of
liver-speci¢c genes such as phosphoenolpyruvate carbooxy-
kinase [32^34], it is reasonable to expect that the SPT/AGT
gene is one of the targets of these factors under physiological
conditions. The binding site(s) seems to partly overlap the
transcription initiation site, indicating that C/EBP may be
involved directly or indirectly in the machinery of initiator-
binding proteins. However, we have not yet determined
whether the initiator-like sequence is a functional element,
and further study is therefore needed to elucidate the precise
mechanism by which C/EBP and the inverted repeat sequence
contribute to an initiation complex.
Our results also indicated the possibility that one of the
C/EBP binding sites overlaps a binding site for a di¡erent
kind of protein (Fig. 4C, complex II). When the 3P-region
(+68^+70) from the start site was mutated, an unknown fac-
tor did not bind to the downstream promoter, whereas the
binding of C/EBP to the promoter was not a¡ected. In addi-
tion, this mutation increased the SPT/AGT promoter activity.
These results suggest that a novel factor may function as a
transcriptional repressor, or that the mutations unintention-
ally produced a stronger initiator and the behavior of complex
(II) is not directly involved in the promoter activation. How-
ever, the latter seems to be less likely, because the sequence
around the start site became much less homologous to the
consensus initiator sequence by the mutations. Further study
is needed to identify the transcription factor so that its role
will be fully understood.
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